Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery

Thrombosis Research

Volumn 96, Issue 4, 1999, Pages 261-268

  Kohda, Noriyuki ^a   Tani, Takeshi ^a   Nakayama, Sunao ^a   Adachi, Tomoya ^a   Marukawa, Keiko ^a   Ito, Rieko ^a   Ishida, Kazuaki ^a   Matsumoto, Yutaka ^a   Kimura, Yukio ^a  

^a Tokushima Research Institute   (Japan)

Author keywords

Carotid artery; Cilostazol; Platelet aggregation; Thrombus

Indexed keywords

ANTICOAGULANT AGENT; CILOSTAZOL; THROMBOXANE B2; TICLOPIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; BLOOD VESSEL INJURY; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; DRUG EFFECT; HEART RATE; HEMODYNAMICS; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SWINE; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; CAROTID ARTERIES; DISEASE MODELS, ANIMAL; ELECTRIC STIMULATION; ENDOTHELIUM, VASCULAR; HEMODYNAMIC PROCESSES; MALE; ORCHIECTOMY; PLATELET AGGREGATION; SEROTONIN; SWINE; TETRAZOLES; THROMBOSIS; THROMBOXANE B2; TICLOPIDINE;

EID: 0032700659     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00109-7     Document Type: Article

References (22)

1. MRC European carotid surgery trial. Interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis Lancet. 337:1991;1235-1243.
2. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 325:1991;445-453.
3. Collaborative overview of randomized trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ. 308:1994;81-106.
4. Gent M., Blakely J.A., Easton J.D., Ellis D.J., Hachinski V.C., Harbison J.W., Panak E., Roberts R.S., Sicurella J., Turpie A.G.G. The Canadian American ticlopidine study (CATS) in thrombotic stroke. Lancet. 1:1989;1215-1220.
5. Hass W.K., Easton J.D., Adams H.P., Pryse-Phillips W., Molony B.A., Anderson S., Kamm B., for the Ticlopidine Aspirin Stroke Study Group A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med. 321:1989;501-507.
6. Money S.R., Herd J.A., Isaacsohn J.L., Davidson M., Cutler B., Heckman J., Forbes W.P. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 27:1998;267-275.
7. Dawson D.L., Cutler B.S., Meissner M.H., Strandness E. Cilostazol has beneficial effects in treatment of intermittent claudication. Results from a multicenter, randomized, prospective, double-blind trial. Circulation. 98:1998;678-686.
8. Okuda Y., Kimura Y., Yamashita K. Cilostazol. Cardiovasc Drug Rev. 11:1993;451-465.
9. Kimura Y., Tani T., Kanbe T., Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombus. Drug Res. 35:1985;1144-1148.
10. Matsumoto Y., Marukawa K., Okumura H., Adachi T., Tani T., Kimura Y. Comparative study of antiplatelet drugs in vitro. Distinct effects of cAMP-elevating drugs and GP IIb/IIIa antagonists on thrombin-induced platelet responses Thromb Res. 95:1999;19-29.
11. Minami N., Suzuki Y., Yamamoto M., Kihara H., Imai E., Wada H., Kimura Y., Ikeda Y., Shiku H., Nishikawa M. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sci. 61:1997;383-389.
12. Rote W.E., Mu D., Roncinske R.A., Frelinger A.L. III, Lucchesi B.R. Prevention of experimental carotid artery thrombosis by applaggin. J Pharm Exp Ther. 267:1993;809-814.
13. 2] prevents arterial but not venous rethrombosis. J Cardiovasc Pharm. 26:1995;241-250.
14. Mousa S.A., Mu D., Lucchesi B.R. Prevention of carotid artery thrombosis by oral platelet GPIIb/IIIa antagonist in dogs. Stroke. 28:1997;830-836.
15. Rebello S.S., Driscoll E.M., Lucchesi B.R. TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog. Stroke. 28:1997;1789-1796.
16. Wester P., Dietrich D., Prado R., Watson B.D., Globus M.Y.T. Serotonin release into plasma during common carotid artery thrombosis in rats. Stroke. 23:1992;870-875.
17. Akiyama H., Kudo S., Shimizu T. The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man. Drug Res. 35:1985;1124-1132.
18. Merino A., Cohen M., Badimon J.J., Fuster V., Badimon L. Synergistic action of severe wall injury and shear forces on thrombus formation in arterial stenosis. Definition of a thrombotic shear rate threshold J Am Coll Cardiol. 24:1994;1091-1094.
19. Kroll M.H., Hellums J.D., McIntire L.V., Schafer A.I., Moake J.L. Platelets and shear stress. Blood. 88:1996;1525-1541.
20. Nuttall A., Smith H.J., Loveday B.E. A clinically relevant model of heart failure. Effects of ticlopidine Cardiovasc Res. 19:1985;187-192.
21. Kawamura K., Watanabe K., Kimura Y. Effect of cilostazol, a new antithrombotic drug, on cerebral circulation. Drug Res. 35:1985;1149-1154.
22. Akashi A., Tamura K., Hirohashi M., Watanabe K., Kasahara K. Pharmacological studies on ticlopidine, a new platelet aggregation inhibitor. Drug Res. 30:1980;409-441.